It may seem obvious when it comes to the question of what is a mutual fund NAV. But going by the queries we often receive from our customers, there are misconceptions over what the NAV indicates, and how you should use it. Here is a look at how mutual fund NAVs should and should not be viewed.
Insurance policies are always purchased with the hope that they will never be needed. Personal accident covers are no exception. Many of us would rather not even think about accidents – but this shouldn’t stop us from thinking about protection for us and our dependents against the financial burden, in the eventuality that an accident does occur.
What is Sensex, how is it computed and why is it so important? It is highly unlikely that one would go through a stock market related conversation and not hear the word ‘Sensex’. Frequently described as the pulse or a barometer of market sentiment and the economy, which way and how much the Sensex moves, can make or break their day for may.
As per IRDAI (Health Insurance) Regulations 2016, porting means ‘the right accorded to an individual health insurance policyholder (including family cover), to transfer the credit gained for pre-existing conditions and time bound exclusions, from one insurer to another or from one plan to another plan of the same insurer’. In short, should you decide to move from one health insurer to another, or from one plan to another with the same insurer, porting helps you retain some of the benefits you have earned on your old policy.
The LIC Arogya Rakshak falls somewhere in between a hospital daily-cash policy and a critical illness cover. It is an individual health insurance plan from a life insurer that provides a definite benefit unlike indemnity health covers that only reimburse hospital expenses. It can be taken either on an individual or a family floater basis, with one member being the Principal Insured (PI).
Sugar industry: Will ethanol blending prove a turning point? Commodity prices have been rallying globally in the last few weeks, with some folks speculating if this is the start of a new commodity ‘super-cycle’. With all eyes on commodity stocks, the sweetest of them all, sugar companies, too have been trending higher. Leading players such as Balrampur Chini Mills Limited, Dhampur Sugar Mills Limited and EID Parry saw their stocks hit 52-week highs in June (Balrampur Chini Mills Limited and Dhampur Sugar Mills Limited even hit all-time highs) and some stock prices even doubled in the last six months. Here we take a look at the sugar sector in India and its nuances.
RITES Limited, is a public sector undertaking (PSU) specializing in consultancy work in the fields of transport, infrastructure and related technologies. Established under the aegis of Indian Railways, this Miniratna (Category I) Schedule A PSU, was established in 1974 and was listed in the stock exchanges in July 2018. The Ministry of Railways owns 72.02% of the shares in RITES Limited. Starting out as an infrastructure consultant, the company evolved itself to offer both consulting and turnkey execution of engineering projects, leasing services and exports for the Indian Railways.
Growth estimates are being placed at a CAGR of around 10% for the next five years for the diagnostics sector, presenting a very attractive opportunity to players that are ready and able to take advantage. Dr Lal Path Labs is a leading diagnostics player, building up its presence outside its traditional stronghold of Delhi.
The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research services before onboarding. History, Present business and Background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services. Terms and conditions of Research Services: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Analyst never guarantees the returns on the recommendation provided. Investor shall take note that Investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The Research Analyst shall not be responsible for any loss to the Investors. Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made there under against the Research Analyst relating to Research Analyst services. Details of its associates: No associates. Disclosures with respect to Research and Recommendations Services: The Research Analyst or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of Research Analyst services. Such conflict of interest shall be disclosed to the client as and when they arise. Research Analyst or its directors or its employee or its associates have not received any compensation from the company which is subject matter of recommendation. Research Analyst or its directors or its employee or its associates have not managed or co-managed the public offering of any company. Research Analyst or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation. The subject company was not a client of Research Analyst or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided. Research Analysts or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.
Full disclosures and disclaimers
Compliance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
Grievance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
